The RED-C Study for Patients with Liver Cirrhosis and Medically Controlled Ascites

Clinical Trial Title

The RED-C Study: A Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion Tablets for the Delay of Encephalopathy Decompensation in Patients with Cirrhosis

National Clinical Trial Number:


Contact Information

Clinical Trial Protocol Description:

The RED-C study is designed to assess how well Rifaximin soluble solid dispersion tablets work to delay hepatic encephalopathy (confusion due to liver cirrhosis) in patients with liver cirrhosis related to any kind of liver disease. Patients will need to attend regular research visits at the Rush downtown campus.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have been diagnosed with liver cirrhosis with medically controlled ascites. 

You will be excluded from the study if any of the following criteria apply to you:

  • Have experienced an episode of hepatic encephalopathy in the past.
  • Have taken or be taking rifaximin 550 mg and/or lactulose for a suspected hepatic encephalopathy episode.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Nancy Reau, MD

Contact Information

Grace Lin

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more